Apixaban in patients with atrial fibrillation. - Wikidata - awgldk - TriplyDB

Apixaban in patients with atrial fibrillation.

Apixaban in patients with atrial fibrillation.

http://www.wikidata.org/entity/Q34163710

about

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation Stroke prevention in atrial fibrillation: latest clinical trials and guidelines How and When to Screen for Atrial Fibrillation after Stroke: Insights from Insertable Cardiac Monitoring Devices Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions Emerging Tools for Stroke Prevention in Atrial Fibrillation Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review Novel oral anticoagulants and the 73rd anniversary of historical warfarin Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The evolution of anticoagulant therapy Managing atrial fibrillation in the very elderly patient: challenges and solutions How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis Apixaban and oral implications Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review Atrial fibrillation in heart failure: what should we do?Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care Ophthalmic regional blocks: management, challenges, and solutions TIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management Antithrombotic management of atrial fibrillation in the elderly Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute What do we currently know about metabolic syndrome and atrial fibrillation?Managing anticoagulation for atrial fibrillation: current issues and future strategies Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy Safety of new oral anticoagulant drugs: a perspective An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature The Cost Effectiveness of LAA Exclusion Atrial fibrillation management in older heart failure patients: a complex clinical problem The current approach of atrial fibrillation management Clinical and Economic Implications of AF Related Stroke

P2860

Q21284803-8F482F95-CA2C-4241-8E77-D4670B777B1D Q22241786-2F8A152B-AE3B-4BEF-9EC8-5FED5A7DCFBE Q24202280-0A938D1D-07B6-4F4D-AE09-81448FAD94DC Q24628390-A19CAB60-866E-48B2-8533-D2259278C58A Q26747267-79BFDF1A-CAAA-4A5D-AAAC-60DBB7392521 Q26750767-963C4F5C-4661-4D4B-8469-42E912B81C47 Q26764853-0CF009E9-4D63-4253-9C0C-8A4D4B722198 Q26765023-0678EE2C-7EAC-41A1-A0F1-EE59EC4A4495 Q26765949-B3F1E29F-DE3B-4F7A-AD6F-6A3137B901AA Q26771544-C77B116F-DA5C-4C7D-B237-12772BEB1609 Q26771564-ED696A67-EF36-4577-AA70-82E03FCFA943 Q26771859-5CBBD2AF-693D-4D24-9930-961A7A97346E Q26775877-E9B7EEF9-E533-427C-97A4-6E1351749D99 Q26776413-0D770A23-9A1A-41B5-BA27-F44B3D5592BA Q26777365-AF73A07B-549A-48C4-8CFD-BE64F1C217D6 Q26780328-2A2A21FE-9A88-46C0-AD08-C4DD1ED2F16B Q26781181-299A8EDB-CC26-4B13-AE4C-BCF81BF1E987 Q26783455-2EF3B464-1C69-4E79-83FB-4A3A20DA6088 Q26784426-6DF8EF51-5BC2-4BA9-A8C9-2611AC44CC73 Q26785480-237FEE6B-E0AD-4B35-8C1A-4BB28609BFBA Q26796407-3F872E14-5C0A-4BBE-83A1-73A19D88DEEA Q26796466-C7D27AA8-E68F-488A-BB26-82E3675C3777 Q26799394-5989C1A7-E3BE-45AA-86CA-1191493FAA99 Q26799571-CE9AA8BE-5C99-4B70-8D80-1E43CDBF3F1A Q26801820-7FD67CE9-2A32-401B-A889-0A944F9E8FDE Q26801895-C9261B12-B60F-4C52-96FF-B8BADC198BEF Q26827113-FC7E0413-E7BC-4119-AEA1-72E0EBA49171 Q26851235-11DC9C9F-031E-4B71-A3C2-D7E1F9A63B42 Q26864437-328A23C5-69BA-43D6-AE5C-6984D292DF8C Q26991728-44C75F60-1BA0-4D03-8A98-4B7DBEF0A4E6 Q26998331-F7F75DAC-A363-47A1-B475-D867BC5FC1F2 Q27016072-5BA1C50A-AC4D-4BCD-BE31-5634B0B8DEF3 Q27027953-EB2F94F5-2BFD-4EE8-9B3D-96CCAF8A1CB3 Q27337981-4DAF16D6-3632-460E-A79A-CE017C9A7C50 Q27341873-F286728D-1BE3-4A1B-B358-C179D5563750 Q27497485-BB0256F0-7977-4402-BD1E-FBDA9D9D62B0 Q28072579-F7196F78-63A4-4DE4-8E51-0475B128EE47 Q28076170-1215A911-A74B-4626-AE79-CBC48FEA9948 Q28076171-2E1E3FF0-F688-4103-9E4D-DC2EB153F7C4 Q28077788-C5B3EE34-C426-4A9A-847E-32CF60743057

P2860

Apixaban in patients with atrial fibrillation.

http://www.wikidata.org/entity/Q34163710

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Apixaban in patients with atrial fibrillation.

@ast

Apixaban in patients with atrial fibrillation.

@en

Apixaban in patients with atrial fibrillation.

@nl

type

label

Apixaban in patients with atrial fibrillation.

@ast

Apixaban in patients with atrial fibrillation.

@en

Apixaban in patients with atrial fibrillation.

@nl

prefLabel

Apixaban in patients with atrial fibrillation.

@ast

Apixaban in patients with atrial fibrillation.

@en

Apixaban in patients with atrial fibrillation.

@nl

P1433

Q34163710-BBF02822-4650-4179-8CEC-7F2FBB6402B6

P1476

Q34163710-7992BA3E-243E-4EFE-8085-86D9C8048F37

P2093

Q34163710-08791901-66A5-4756-AF78-782C908EE848

Q34163710-13E6A547-CB79-4006-98D7-9B7EB4DF1FFD

Q34163710-212DB7CF-520E-4E2A-95CB-03E20D3B3C8B

Q34163710-3600D49B-1DA3-44B6-AE58-F440DE8A5BD5

Q34163710-363D640A-C781-48A0-9839-7F6B5DDA67D9

Q34163710-3F9DC650-396A-4188-B826-A74BB5EE9D87

Q34163710-4B98016A-A3C3-4338-9748-BEEC2D1F9582

Q34163710-4BF17520-7331-494A-8E44-92CB0B2CFC73

Q34163710-4EAF6F6D-99D6-4B03-B9C1-1B0D06953191

Q34163710-519396CC-6873-4A4D-8DA3-D898F23B60FF

P304

Q34163710-3E127541-C5C5-4428-AEB1-C84A5A3C63BD

P31

Q34163710-3E8F2FFE-7686-4116-84D2-39AD6B357EC3

P356

Q34163710-59621981-FD18-448A-AB42-A840666339C7

P407

Q34163710-F05A24EE-24AA-4B68-B441-D52B2515E4E4

P433

Q34163710-88FFA4DC-B63B-45C4-ACC6-C56B124806F6

P478

Q34163710-E3C8A6E8-5290-4192-94AD-A480038AE84D

P50

Q34163710-55217680-DA50-47C9-9D3C-B1F044498749

Q34163710-583674BC-2E36-438A-B5AF-B14749517ACC

Q34163710-82F87F1D-BBE1-4DAC-A4BF-861059057AC6

Q34163710-A7F5972F-4CD5-403A-84DC-86B7E52235E0

Q34163710-AE49A8A4-F931-43C2-873F-E519D8C87581

Q34163710-F185E893-D42B-4822-81CF-98F7CF0D1031

P577

Q34163710-8570C8B0-6AFA-45DE-AB66-FCC36611E26C

P698

Q34163710-A9833F7C-70F9-430A-A97C-D1A6922FE306

P921

Q34163710-29BD77BF-2FB8-4A0A-9181-BFCDA64E3559

P356

P1433

The New England Journal of Medicine

P1476

Apixaban in patients with atrial fibrillation.

@en

P2093

AVERROES Steering Committee and Investigators

http://www.w3.org/2001/XMLSchema#string

Alexander Parkhomenko

http://www.w3.org/2001/XMLSchema#string

Alvaro Avezum

http://www.w3.org/2001/XMLSchema#string

Andrzej Budaj

http://www.w3.org/2001/XMLSchema#string

Antonio Gonzalez-Hermosillo

http://www.w3.org/2001/XMLSchema#string

Antonio L Dans

http://www.w3.org/2001/XMLSchema#string

Basil S Lewis

http://www.w3.org/2001/XMLSchema#string

Campbell Joyner

http://www.w3.org/2001/XMLSchema#string

Fernando Lanas-Zanetti

http://www.w3.org/2001/XMLSchema#string

Gayle Lewis

http://www.w3.org/2001/XMLSchema#string

P304

806-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1007432

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Christoph Diener

Martin O'Donnell

John W. Eikelboom

Gregory Y. H. Lip

P577

2011-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21309657

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation